Tuesday, October 19, 2021 10:14:08 AM
Recent WINT News
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 01:53:39 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2024 01:01:49 PM
- Windtree Announces Leadership Transition Plan With Industry Veterans • GlobeNewswire Inc. • 11/14/2024 01:00:00 PM
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Hong Kong • GlobeNewswire Inc. • 11/04/2024 01:00:00 PM
- Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3 • GlobeNewswire Inc. • 10/30/2024 12:00:00 PM
- Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World • GlobeNewswire Inc. • 10/23/2024 12:00:00 PM
- Windtree To Present at the ThinkEquity Conference on October 30th • GlobeNewswire Inc. • 10/21/2024 12:00:00 PM
- Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan • GlobeNewswire Inc. • 10/17/2024 12:15:00 PM
- Windtree Announces Publication of Positive Istaroxime Phase 2b Study Trial Design • GlobeNewswire Inc. • 10/09/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 11:46:52 AM
- Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/30/2024 12:15:00 PM
- Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET • GlobeNewswire Inc. • 09/26/2024 08:05:00 PM
- Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/25/2024 12:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/25/2024 12:05:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/24/2024 09:21:14 PM
- Windtree Completes Enrollment of Phase 2b Study of Istaroxime in Early Cardiogenic Shock • GlobeNewswire Inc. • 09/04/2024 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/04/2024 04:15:11 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:10:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 09/03/2024 01:09:25 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/03/2024 11:22:46 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/23/2024 08:15:59 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/21/2024 08:55:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:30:55 PM
Kona Gold Beverage, Inc. Updates Multi-Million Dollar Merger and Posts Over $1.2 Million in Q3 Revenues • KGKG • Nov 15, 2024 10:36 AM
HealthLynked Corp. Announces Third Quarter and Year-to-Date 2024 Results with Strategic Restructuring, Third-Party Debt Repayment, and Core Technology Focus • HLYK • Nov 15, 2024 8:00 AM
Alliance Creative Group (ACGX) Releases Q3 2024 Financial and Disclosure Report with an increase of over 100% in Net Income for 1st 9 months of 2024 vs 2023 • ACGX • Nov 14, 2024 8:30 AM
Unitronix Corp. Publishes Its Cryptocurrency Portfolio Strategy • UTRX • Nov 14, 2024 8:05 AM
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM